Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 4913 - 4920 of 12009 results
Changes to Preference Practices Under New Bankruptcy Law
September 4, 2019| Blog| Viewpoint
Proposed H-1B Cap Registration Fee Rule Published by DHS
September 4, 2019| Alert| Viewpoint
Processing Delays Expected to Continue For All Trusted Traveler Program Applications
September 4, 2019| Blog| Viewpoint
New Convention Aims to Make Mediated Settlements an Attractive Means of Resolution of International Disputes . . . But Will It?
September 3, 2019| Blog| Viewpoint
ITC Domestic Industry Products Do Not Need to Be Commercially Available
September 3, 2019| Blog| Viewpoint
Part 2 Proposed Rule Brings Clarity and Reduces Regulatory Burdens for Substance Use Disorder Providers, but Challenges Remain
September 3, 2019| Blog| Viewpoint
Patent Prosecution and FDA Compliance Expenses May Help Satisfy the ITC’s Domestic Industry Requirement
September 3, 2019| Blog| Viewpoint
Join Us for a Webinar on MA Paid Family and Medical Leave
August 30, 2019| Blog| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|